Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BCT022
MIFTS: 56

Bacterial Infectious Disease

Categories: Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bacterial Infectious Disease

About this section

MalaCards integrated aliases for Bacterial Infectious Disease:

Name: Bacterial Infectious Disease 12 15
Bacterial Infections 43

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:104
MeSH 43 D001424
NCIt 49 C2890
SNOMED-CT 67 301811001
ICD10 32 A49 A49.9
UMLS 71 C0004623
Sources

Summaries for Bacterial Infectious Disease

About this section
Disease Ontology : 12 A disease by infectious agent that results in infection, has material basis in Bacteria.

MalaCards based summary : Bacterial Infectious Disease, also known as bacterial infections, is related to opportunistic bacterial infectious disease and commensal bacterial infectious disease. An important gene associated with Bacterial Infectious Disease is CRP (C-Reactive Protein), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Ciprofloxacin and Penicillin G have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, skin and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Sources

Related Diseases for Bacterial Infectious Disease

About this section

Diseases related to Bacterial Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1297)
# Related Disease Score Top Affiliating Genes
1 opportunistic bacterial infectious disease 35.3 TNF IFNG CRP
2 commensal bacterial infectious disease 35.1 TNF TLR4 TLR3 TLR2 MYD88 IL6
3 primary bacterial infectious disease 35.0 TNF TLR4 TLR3 TLR2 NOD2 MYD88
4 myd88 deficiency 34.7 TLR4 TLR2 MYD88 IRAK4
5 irak4 deficiency 33.6 TLR4 TLR2 MYD88 IRAK4
6 leukocyte adhesion deficiency, type i 33.5 IL17A CSF3 CCR6
7 chorioamnionitis 33.5 TNF TLR4 IL6 IL1B IL10 CXCL8
8 syphilis 33.5 TNF IL6 IL17A IFNG CRP CCR6
9 q fever 33.4 TNF TLR4 TLR2 NOD2 MYD88 IL6
10 common variable immunodeficiency 33.4 TNF TLR2 NOD2 IL6 IL1B IL10
11 neutropenia 33.4 TNF TLR4 IL6 IL1B IL10 IFNG
12 erysipelas 33.3 TNF IL6 IL1B CRP
13 bacterial meningitis 33.3 TNF TLR4 TLR2 IL6 IL1B IL17A
14 pyelonephritis 33.3 TNF TLR4 IL6 IL1B IL10 IFNG
15 osteomyelitis 33.3 TNF TLR4 TLR2 NOD2 IL6 IL1B
16 sickle cell anemia 33.3 TNF IL6 CXCL8 CSF3 CRP
17 leprosy 3 33.3 TNF TLR4 TLR3 TLR2 NOD2 IL6
18 blepharitis 33.3 TNF IL6 IL1B CCR6
19 tracheitis 33.3 TNF IL6 CRP
20 cellulitis 33.2 TNF IL6 IL1B IL17A IL10 IFNG
21 pulpitis 33.2 TNF TLR4 IL6 IL1B CXCL8 CCR6
22 scabies 33.2 IL10 CXCL8 CSF3 CCR6
23 carbuncle 33.2 TNF IL6 IL1B
24 chronic granulomatous disease 33.2 TNF IL1B IL17A IFNG CXCL8 CSF3
25 impetigo 33.2 IL6 CCR6 CAMP
26 urethritis 33.2 TNF TLR4 TLR2 IL6 IL1B DEFB4A
27 cystic fibrosis 33.2 TNF TLR4 TLR2 IL6 IL1B IL17A
28 bacterial pneumonia 33.2 TNF TLR4 TLR3 TLR2 IL6 IL1B
29 ulcerative colitis 33.1 TNF TLR4 NOD2 IL6 IL1B IL17A
30 hyper ige syndrome 33.1 TNF TLR4 TLR3 TLR2 IRAK4 IL6
31 psoriasis 33.1 TNF TLR2 NOD2 IL6 IL1B IL17A
32 spotted fever 33.0 TNF IL10 IFNG
33 nocardiosis 33.0 TNF IFNG CRP
34 paratyphoid fever 33.0 TNF IL1B IFNG CRP CCR6
35 lyme disease 33.0 TNF TLR2 IL6 IL1B IL17A CRP
36 epidemic typhus 33.0 TLR4 TLR2 IL10 CRP
37 leptospirosis 33.0 TNF TLR2 IL6 IL1B IL10 IFNG
38 legionellosis 33.0 TNF TLR4 TLR2 MYD88 IL6 IL1B
39 typhoid fever 33.0 TNF TLR4 IL6 IL1B IFNG CRP
40 tetanus 33.0 TNF IL6 IL1B IL10 IFNG CRP
41 campylobacteriosis 33.0 TLR4 IL1B IFNG
42 trachoma 33.0 TNF IL6 IL17A IL10
43 macs syndrome 33.0 TNF IL10 IFNG
44 tularemia 33.0 TNF TLR4 TLR2 MYD88 IL1B IL17A
45 listeriosis 33.0 TNF TLR4 TLR2 MYD88 IL6 IL1B
46 brucellosis 33.0 TNF TLR4 IL6 IL17A IL10 IFNG
47 plague 33.0 TNF TLR4 TLR3 TLR2 MYD88 IL6
48 melioidosis 32.9 TNF TLR4 TLR2 NOD2 IL6 IL10
49 pertussis 32.9 TNF TLR4 MYD88 IRAK4 IL6 IL1B
50 acute proliferative glomerulonephritis 32.9 TNF CRP CCR6

Graphical network of the top 20 diseases related to Bacterial Infectious Disease:



Diseases related to Bacterial Infectious Disease
Sources

Symptoms & Phenotypes for Bacterial Infectious Disease

About this section

GenomeRNAi Phenotypes related to Bacterial Infectious Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.5 CXCL8 IL10 IL17A IL1B MYD88 NOD1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.5 CXCL8 IL10 IL17A IL1B MYD88 NOD1

MGI Mouse Phenotypes related to Bacterial Infectious Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 CAMP CCR6 CSF3 IFNG IL10 IL17A
2 immune system MP:0005387 10.25 CAMP CCR6 CRP CSF3 IFNG IL10
3 homeostasis/metabolism MP:0005376 10.21 CCR6 CRP IFNG IL10 IL17A IL1B
4 cardiovascular system MP:0005385 10.2 CCR6 CRP IFNG IL10 IL1B IL6
5 digestive/alimentary MP:0005381 10.09 IFNG IL10 IL17A IL6 MYD88 NOD2
6 integument MP:0010771 9.91 CSF3 IFNG IL10 IL17A IL1B IL6
7 neoplasm MP:0002006 9.81 IFNG IL10 IL1B IL6 MYD88 TLR2
8 respiratory system MP:0005388 9.61 IFNG IL10 IL17A IL6 MYD88 TLR2
9 skeleton MP:0005390 9.32 IFNG IL10 IL17A IL1B IL6 MYD88
Sources

Drugs & Therapeutics for Bacterial Infectious Disease

About this section

Drugs for Bacterial Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 538)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
2
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
3
Zidovudine Approved Phase 4 30516-87-1 35370
4
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
5
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
6
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
7
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
8
Cilastatin Approved, Investigational Phase 4 82009-34-5 5280454 6435415
9
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
10
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
11
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 2826718 468682
12
Doripenem Approved, Investigational Phase 4 148016-81-3 73303
13
Retapamulin Approved Phase 4 224452-66-8 6918462
14
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
15
Sodium citrate Approved, Investigational Phase 4 68-04-2
16
carbamide peroxide Approved Phase 4 124-43-6
17
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
18
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
19
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
20
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
21
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
22
Promethazine Approved, Investigational Phase 4 60-87-7 4927
23
Histamine Approved, Investigational Phase 4 51-45-6 774
24
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
26
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
27
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
28
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
29
Povidone-iodine Approved Phase 4 25655-41-8
30
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6447131
31
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4 90-89-1 3052
32
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
33
Vancomycin Approved Phase 4 1404-90-6 14969 441141
34
Telavancin Approved Phase 4 372151-71-8
35
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
36
Nafcillin Approved, Investigational Phase 4 985-16-0, 147-52-4 8982
37
Cefazolin Approved Phase 4 25953-19-9 656510 33255
38
Metronidazole Approved Phase 4 443-48-1 4173
39
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
40
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
41
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
42
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
43
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
44
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
45
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
46
Acetaminophen Approved Phase 4 103-90-2 1983
47
Lactulose Approved Phase 4 4618-18-2 11333
48
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
49
Clarithromycin Approved Phase 4 81103-11-9 84029
50
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005

Interventional clinical trials:

(show top 50) (show all 927)
# Name Status NCT ID Phase Drugs
1 Clinical and Microbiological Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients Unknown status NCT02117986 Phase 4 colistin
2 Adverse Drug Reactions of Different Brands of Ceftazidime Injection Unknown status NCT00173901 Phase 4 ceftazidime
3 An Open-label, Randomized Equivalence Trial and Cost-effectiveness Analysis of Ertapenem Versus Other Carbapenems for Treatment of Extended -Spectrum Beta-Lactamase (ESBL)-Producing Gram-negative Bacterial Infections Unknown status NCT01297842 Phase 4 Ertapenem;Meropenem or Imipenem
4 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Surgery in Patients With Suppurative or Gangrenous Appendicitis Unknown status NCT03380793 Phase 4 morinidazole
5 Noroxin Efficacy and Safety Trial Unknown status NCT03506256 Phase 4 Norfloxacin 400 MG
6 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Levofloxacin and Sequential of Levofloxacin in Women With Pelvic Inflammatory Disease Unknown status NCT03391440 Phase 4 morinidazole
7 Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy. Unknown status NCT01572597 Phase 4 10RAC+acetylcystein;10RAC+metronidazole
8 Rifaximin Predicts the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial Unknown status NCT02074280 Phase 4 rifaximin
9 Rifaximin Reduces the Complications of Decompensated Cirrhosis Unknown status NCT02190357 Phase 4 Rifaximin
10 Systematic Empirical vs. Test-guided Anti-tuberculosis Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating Antiretroviral Therapy With CD4 Cell Counts <100/mm3: the STATIS Randomized Controlled Trial Unknown status NCT02057796 Phase 4 ART (Atripla, Truvada, Efavirenz, Combivir);Rifampin, isoniazid, pyrazinamide, ethambutol
11 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
12 Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin in the Treatment of Methicillin-resistant Staphylococcus Aureus（MRSA） Blood Stream Infection (Septicemia) and Endocarditis in Chinese Patients Unknown status NCT02443064 Phase 4 Vancomycin
13 Studying the Role of N-Acetyl Cysteine Either Alone or in Combination With Metronidazole in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
14 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics? Unknown status NCT02171338 Phase 4
15 Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome Unknown status NCT03148444 Phase 4 cefalexin 500 mg qid or roxithromycin 150 mg bid
16 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
17 The Treatment of Periodontal Diseases. A Randomized, Blinded, Five Years Follow-up, Four-arm, Placebo Controlled Clinical Intervention Trial Unknown status NCT01318928 Phase 4 Metronidazol
18 Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections Completed NCT00147511 Phase 4 linezolid
19 Multicenter Open-label RCT to Compare Colistin Alone vs. Colistin Plus Meropenem Completed NCT01732250 Phase 4 Colistin;Meropenem
20 Randomized, Open-label, Comparative Study of Zosyn (Pip/Tazo [12g/1.5g]) Administered by Daily 24hr Continuous Infusion vs Zosyn (Pip/Tazo) [3g/0.375g]) q6h for the Treatment of Hospitalized Patients With Complicated Intra-abdominal Infection Completed NCT00044928 Phase 4 Piperacillin/Tazobactam
21 Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) Producing Bacteria Completed NCT00488189 Phase 4 Tazocin (pipercillin/tazobactam)
22 Association of Antibiotic Utilization Measures and Control of ESBLs Producing Bacteria Completed NCT00478855 Phase 4 Tazocin (Piperacillin/Tazobactem)
23 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Completed NCT01968395 Phase 4 Caspofungin 70 mg
24 A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Tears of Healthy Volunteers Following a Single Ocular Administration Completed NCT00575367 Phase 4 AzaSite (azithromycin ophthalmic solution);Vigamox (moxifloxacin hydrochloride ophthalmic solution)
25 A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Conjunctiva of Healthy Volunteers Following a Single Ocular Administration Completed NCT00564447 Phase 4 Azithromycin;Moxifloxacin
26 A Multi-Center, Open-Label, Randomized Study of the Pharmacokinetics of Azithromycin Versus Moxifloxacin in Conjunctiva and Aqueous Humor Following Single or Multiple Ocular Administration of AzaSite Ophthalmic Solution, 1% or Vigamox in Subjects Undergoing Routine Cataract Surgery Completed NCT00575380 Phase 4 AzaSite Eye Drops;Vigamox Eye Drops
27 Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections Completed NCT03233438 Phase 4 Dalbavancin;Usual Care
28 Association of Antibiotic Utilization Measures and Control of Extended-spectrum-lactamases (ESBLs) Completed NCT00254696 Phase 4 Extended-Spectrum-Lactamases (ESBLs)
29 An Open-Label, Two-Treatment, Two-Period, Randomized Cross-Over Study To Assess The Bioequivalence Between Commercial Doxycycline Carragenate And Monohydrate Tablet Formulations In Normal Healthy Male Subjects Completed NCT00939562 Phase 4 doxycycline monohydrate tablet;doxycycline carragenate tablet
30 Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis Completed NCT00406198 Phase 4
31 Dispositivo Adsorbente Con Polymyxina B Immobilizzata Nello Shock Settico - Studio Clinico Randomizzato e Prospettico, Multicentrico Completed NCT00629382 Phase 4
32 An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months Completed NCT00555061 Phase 4 Retapamulin Ointment, 1%
33 Prospective, Double-Blind, Randomized, Placebo-Controlled Trial of Single-Dose Cefuroxime Prophylaxis in Herniated Disk Surgery Completed NCT00530400 Phase 4 cefuroxime;placebo
34 A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents Completed NCT01289847 Phase 4
35 Comparison of Amukin Versus Biseptine Use for Dressing Application of Epicutaneocavous Catheters for Nosocomial Infection Prevention Completed NCT00389558 Phase 4
36 A Prospective, Multi-Center, Open-Label Study to Compare the POCone® With the UBiT®-IR300 in Measurement of 13CO2/12CO2 Ratio in Breath Samples Collected From Pediatric Subjects Ages 3 to 17 Years With Upper Gastrointestinal Signs and Symptoms Completed NCT01623154 Phase 4
37 An Open Observational Study For The Rabeprazole Administration In Adult Subjects With Helicobacter Pylori (H. Pylori) Infection Completed NCT00216450 Phase 4 rabeprazole sodium
38 Steroids for Corneal Ulcers Trial Completed NCT00324168 Phase 4 Antibiotics;Topical corticosteroid;Placebo
39 Randomized Clinical Trial to Assess Whether the Duration of Cotrimoxazole Preventive Therapy in HIV Patients With CD4 Counts >350 CD4 Cells/µL by Antiretroviral Treatment Influences the Rate of Carriage of Multidrug-resistant Bacteria Completed NCT03087890 Phase 4 Cotrimoxazole;Placebo
40 Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection Completed NCT01126268 Phase 4 Retapamulin (Altabax)
41 The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers Completed NCT00318201 Phase 4 Erythromycin;Diltiazem
42 Minocycline for Bipolar Disorder Completed NCT01514422 Phase 4 Minocycline
43 Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants - A Study on Interactions by Nonsteroidal Anti Inflammatory Drugs (NSAIDs) With Fluconazole in Respect of Pharmacodynamic Endpoints With Urinary Excretion of Vasoactive Endobiotics Completed NCT02079298 Phase 4 Treatment with fluconazole.;2. Treatment with both fluconazole and Ibuprofen.;3. Treatment with ibuprofen.
44 A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly With Raxibacumab (GSK3068483) Completed NCT02339155 Phase 4 Diphenhydramine
45 Randomized, Multi-Center, Comparative Trial of Short-Course Empiric Antibiotic Therapy Versus Standard Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the Intensive Care Unit (ICU) Completed NCT00410527 Phase 4 Merrem
46 A Randomized, Multicenter, Parallel Group Study to Evaluate Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder Completed NCT01388413 Phase 4 Weekly Oral Cyclic Antibiotic programme
47 A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections Completed NCT00965848 Phase 4 Doripenem
48 The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis Completed NCT00045760 Phase 4 Drotrecogin alfa (activated)
49 A Clinical Pharmacokinetic Study: Is Three Times Weekly Temocillin Appropriate for the Treatment of Severe Gram-negative Infections in Patients With ESRD Treated With Intermittent Hemodialysis? Completed NCT02285075 Phase 4 temocillin PK/PD in haemodialysis
50 Peri-implantitis - Regenerative Treatment With Enamel Matrix Derivative (EMD). Clinical Effects, Microbial Profiles and Molecular Mechanisms. A Randomised Controlled Pilot Study. Completed NCT02500654 Phase 4

Search NIH Clinical Center for Bacterial Infectious Disease

Cochrane evidence based reviews: bacterial infections

Sources

Genetic Tests for Bacterial Infectious Disease

About this section
Sources

Anatomical Context for Bacterial Infectious Disease

About this section

MalaCards organs/tissues related to Bacterial Infectious Disease:

40
Neutrophil, Skin, Liver, Lung, Testes, T Cells, Bone
Sources

Publications for Bacterial Infectious Disease

About this section

Articles related to Bacterial Infectious Disease:

(show top 50) (show all 22262)
# Title Authors PMID Year
1
[HBD-1 and hBD-2 are expressed in cervico-vaginal lavage in female genital tract due to microbial infections]. 54 61
20476598 2010
2
CCL22 is involved in the recruitment of CD4+CD25 high T cells into tuberculous pleural effusions. 61 54
20337996 2010
3
How to use: C-reactive protein. 61 54
20351152 2010
4
Predicting severe bacterial infections in well-appearing febrile neonates: laboratory markers accuracy and duration of fever. 54 61
19949364 2010
5
Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice. 61 54
20171921 2010
6
High-throughput and single-cell imaging of NF-kappaB oscillations using monoclonal cell lines. 61 54
20233427 2010
7
The importance of determining procalcitonin and C reactive protein in different stages of sepsis. 54 61
20192933 2010
8
The role of Toll-like receptor signaling in human immunodeficiencies. 54 61
19430930 2010
9
Phenylbutyrate induces antimicrobial peptide expression. 61 54
19770273 2009
10
Etiology of community-acquired pneumonia in hospitalized children based on WHO clinical guidelines. 54 61
19238436 2009
11
Hypoxia-altered signaling pathways of toll-like receptor 4 (TLR4) in human corneal epithelial cells. 61 54
19960069 2009
12
rBPI(21) promotes lipopolysaccharide aggregation and exerts its antimicrobial effects by (hemi)fusion of PG-containing membranes. 54 61
20027298 2009
13
C-reactive protein as a marker of serious bacterial infections in hospitalized febrile infants. 61 54
19664100 2009
14
The potential role of C-reactive protein in distinguishing cytomegalovirus from tuberculosis and bacterial infections in renal transplant recipients. 54 61
19594772 2009
15
Clinical significance of complement deficiencies. 54 61
19758139 2009
16
Application of ultralow doses of antibodies to interferon-gamma in complex therapy of bacterial infections and prophylaxis of bacterial complications. 54 61
20027351 2009
17
TREM-1 activation alters the dynamics of pulmonary IRAK-M expression in vivo and improves host defense during pneumococcal pneumonia. 61 54
19596984 2009
18
Intracellular receptor for human host defense peptide LL-37 in monocytes. 54 61
19605696 2009
19
The diagnostic and prognostic accuracy of five markers of serious bacterial infection in Malawian children with signs of severe infection. 54 61
19675669 2009
20
Markers that predict serious bacterial infection in infants under 3 months of age presenting with fever of unknown origin. 54 61
19158133 2009
21
Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. 54 61
19479878 2009
22
Diagnostic potential of urinary tumor necrosis factor-alpha in children with acute pyelonephritis. 54 61
19395784 2009
23
Diagnostic and prognostic significance of serum C-reactive protein levels in patients admitted to the department of medicine. 61 54
19365169 2009
24
A toll-like receptor 4 variant is associated with fatal outcome in children with invasive meningococcal disease. 54 61
19067670 2009
25
IL-17 and anti-bacterial immunity: protection versus tissue damage. 61 54
19283706 2009
26
Concentration dependent aggregation properties of chlorhexidine salts. 61 54
18926892 2009
27
The role of infection in the development of non-valvular atrial fibrillation: up-regulation of Toll-like receptor 2 expression levels on monocytes. 61 54
19167648 2009
28
C-reactive protein velocity to distinguish febrile bacterial infections from non-bacterial febrile illnesses in the emergency department. 54 61
19351421 2009
29
Postoperative variation of C-reactive protein and procalcitonin in patients with gastrointestinal cancer. 54 61
19728551 2009
30
Selective excretion of anti-inflammatory cytokine interleukin-10 in a superantigen-inducing neonatal infectious disease. 54 61
19084429 2009
31
IRAK-4 inhibitors for inflammation. 61 54
19689377 2009
32
Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. 54 61
19436694 2009
33
Myeloid differentiation primary response gene 88 is required for the resolution of otitis media. 54 61
18986247 2008
34
[Evaluation of inflammatory and renal injury markers in youngest children with pyelonephritis]. 54 61
19205372 2008
35
Transcriptional regulatory defects in the first intron of Bruton's tyrosine kinase. 54 61
19067895 2008
36
Systematic review of the diagnostic accuracy of C-reactive protein to detect bacterial infection in nonhospitalized infants and children with fever. 54 61
18534215 2008
37
An investigation of the C4 gene arrangement in ethnic Chinese (Taiwanese). 54 61
18680512 2008
38
C-reactive protein as an indicator of aqueductal gliosis and hydrocephaly in neonatal meningitis. 61 54
18581011 2008
39
Functional activity of MD-2 polymorphic variant is significantly different in soluble and TLR4-bound forms: decreased endotoxin binding by G56R MD-2 and its rescue by TLR4 ectodomain. 54 61
18424732 2008
40
Splenic function and IgM-memory B cells in Crohn's disease patients treated with infliximab. 54 61
18240280 2008
41
Stimulus-dependent impairment of the neutrophil oxidative burst response in lactoferrin-deficient mice. 54 61
18321995 2008
42
Toll-like receptor 2 down-regulation in established mouse allergic lungs contributes to decreased mycoplasma clearance. 54 61
18202345 2008
43
Differential regulation of CCL-11/eotaxin-1 and CXCL-8/IL-8 by gram-positive and gram-negative bacteria in human airway smooth muscle cells. 54 61
18380907 2008
44
Interleukin-6 concentrations in wound fluids rather than serological markers are useful in assessing bacterial triggers of ulcer inflammation. 54 61
18179556 2008
45
Formyl peptide receptor-mediated ERK1/2 activation occurs through G(i) and is not dependent on beta-arrestin1/2. 54 61
18060741 2008
46
IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. 61 54
18200634 2008
47
Neutrophil function and molecular analysis in severe leukocyte adhesion deficiency type I without separation delay of the umbilical cord. 54 61
17651379 2008
48
[Total white blood cell count, erythrosedimentation rate and C-reactive protein for the detection of serious bacterial infections in 0- to 90-day-old infants with fever without a source]. 54 61
18341874 2008
49
Variable responses of formyl peptide receptor haplotypes toward bacterial peptides. 54 61
18253729 2008
50
Staphylococcal pericarditis, and liver and paratracheal abscesses as presentations in two new cases of interleukin-1 receptor associated kinase 4 deficiency. 61 54
18174872 2008